B. Riley downgraded Augmedix to Neutral from Buy with a price target of $2.35, down from $3, after the company entered into a definitive agreement to be acquired by Commure for $2.35 per share in cash.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AUGX:
- Augmedix to Join Forces with Commure
- Augmedix Discusses AI Tool Success and Expansion Plans
- Augmedix says Go ED has met HCA’s criteria for expansion
- Emergency Services Inc. Partners with Augmedix to Introduce Generative AI Solution That Relieves Clinician Burnout in Emergency Departments
- Augmedix, Emergency Services team to introduce GenAI solution